Genmab (GMAB)
(Delayed Data from NSDQ)
$28.15 USD
+0.69 (2.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $28.14 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Genmab A/S Sponsored ADR [GMAB]
Reports for Purchase
Showing records 101 - 109 ( 109 total )
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
As Anticipated, DARZALEX Front-Line MAIA Regimen Wins Approval in Europe; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Numerous ASH Abstracts; 3Q19 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
CHMP Issues Positive Opinion on DARZALEX Front-Line MAIA Regimen; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
DARZALEX 3Q19 Sales Reported; Reiterate Buy and Raising PT to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
FDA Approves CASSIOPEIA Regimen for 1L Transplant-Eligible Multiple Myeloma Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
ARZERRA Matches OCREVUS; Positive GRIFFIN and CANDOR Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Management Highlights Pipeline at Genmab Breakfast; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Arzerra Set to Take on Roche''s Ocrevus; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Genmab A/S Sponsored ADR
Industry: Medical - Biomedical and Genetics
Converting to US Listing; Reiterate Buy and $24 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R